Baxter Revenue and Competitors

Chicago, IL USA

Location

$1.7B

Total Funding

Estimated Revenue & Valuation

  • Baxter's estimated annual revenue is currently $12.4B per year.(i)
  • Baxter's estimated revenue per employee is $323,276
  • Baxter's total funding is $1.7B.
  • Baxter's current valuation is $42.9B. (January 2022)

Employee Data

  • Baxter has 38512 Employees.(i)
  • Baxter grew their employee count by 1% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12450M385121%$1.7B$42.9B
#2
$9.8M3768%N/AN/A
#3
$31800M857843%$367M$146B
#4
$4180M133206%$550M$18.5B
Add Company

Baxter International Inc. is a global medical products and services company that, through its subsidiaries, provides critical therapies for people with life-threatening conditions. Baxter's products and services in bioscience (biopharmaceuticals, vaccines, biosurgery and transfusion therapies), medication delivery and renal therapy are used by health-care providers and their patients in more than 100 countries.

keywords:N/A

$1.7B

Total Funding

38512

Number of Employees

$12.4B

Revenue (est)

1%

Employee Growth %

$42.9B

Valuation

N/A

Accelerator

Baxter News

2022-04-19 - 2023 4-star running back Cedric Baxter releases his Top 5

Late to the party with a January offer, the Oklahoma Sooners missed the top 5 for 2023 four-star running back Cedric Baxter.

2022-04-19 - Texas among top schools for four-star RB Cedric Baxter Jr.

The Texas Longhorns are gaining momentum on the recruiting trail for the 2023 cycle. After two commitments on Saturday, the good news...

2022-04-17 - Miami football in good position as finalist for 4-star RB Cedric Baxter

The Miami football program is in a good position with four-star 2023 running back Cedric Baxter after he named the Hurricanes one of his...

2021-09-23 - Baxter International : Announces U.S. Approval and Launch of Ready-To-Use Cardiovascular Medicine Norepinephrine in Premix Formulation

PDF DEERFIELD, Ill. - 2021-09-23 Baxter International Inc. (NYSE:BAX), a global leader in sterile medication production and delivery, today announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of premix Norepinephrine Bitartrate in 5% Dextrose Injection (norepin ...

2021-07-08 - Baxter International : Launches 2030 Corporate Responsibility Commitment to Advance Environmental, Social and Governance Priorities

PDF DEERFIELD, Ill. - Thu, 07/08/2021 - 12:00 Baxter International Inc. (NYSE:BAX), a leading global medical products company, today released its 2020 Corporate Responsibility Report. This year's report details final achievement towards Baxter's 2015-2020 set of corporate responsibility priori ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$30710.3M96634-30%N/A
#2
$132510M1069615%$71.9M
#3
$48410M1333016%N/A